John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Cregg Report - The Major Messages for 2021 in IBD Volume 29, issue 4, April 2022

Figures

  • Figure 1
Author
Hôpital Ambroise Paré, Service d’hépato-gastro-entérologie, 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt
* Correspondance : T. Bazin

SARS-CoV-2 is not the only news ! In IBD, the year 2021 has been rich in novelties. The SEAVUE study, although negative, appears to show that ustekinumab is as effective as adalimumab as first line treatment in Crohn’s disease. The STARDUST study studying the interest of treat-to-target under ustekinumab is also negative, but above all teaches us that treat-to-target is almost becoming a “standard of care”. Of course, the subcutaneous forms of infliximab and vedolizumab are there and will profoundly change our practice. Ultra-processed foods are definitely not only of no interest, but are also associated with an increased risk of developing IBD! Finally, ultrasound continues to prove, if needed, its value in the diagnosis and monitoring of IBD. And let’s not forget that a first episode of proctitis is an STI until proven otherwise.